Boston Trust Walden Corp Decreases Stock Holdings in InMode Ltd. (NASDAQ:INMD)

Boston Trust Walden Corp reduced its holdings in InMode Ltd. (NASDAQ:INMD - Free Report) by 2.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,367,376 shares of the healthcare company's stock after selling 40,695 shares during the quarter. Boston Trust Walden Corp owned about 1.63% of InMode worth $22,835,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in INMD. National Bank of Canada FI grew its position in InMode by 6.2% during the third quarter. National Bank of Canada FI now owns 9,985 shares of the healthcare company's stock valued at $169,000 after buying an additional 579 shares during the period. Carmel Capital Partners LLC boosted its stake in shares of InMode by 6.9% during the 3rd quarter. Carmel Capital Partners LLC now owns 11,511 shares of the healthcare company's stock worth $195,000 after acquiring an additional 741 shares during the last quarter. Franklin Resources Inc. grew its position in shares of InMode by 4.6% during the 3rd quarter. Franklin Resources Inc. now owns 17,559 shares of the healthcare company's stock valued at $292,000 after acquiring an additional 768 shares during the period. Meritage Portfolio Management increased its stake in shares of InMode by 9.5% in the 3rd quarter. Meritage Portfolio Management now owns 14,765 shares of the healthcare company's stock worth $250,000 after purchasing an additional 1,284 shares in the last quarter. Finally, North Growth Management Ltd. lifted its position in InMode by 0.3% during the third quarter. North Growth Management Ltd. now owns 595,000 shares of the healthcare company's stock valued at $10,083,000 after purchasing an additional 2,000 shares in the last quarter. 68.04% of the stock is owned by hedge funds and other institutional investors.

InMode Stock Performance

INMD traded down $0.21 during trading on Friday, reaching $18.04. 1,220,008 shares of the company traded hands, compared to its average volume of 935,887. The company has a market cap of $1.51 billion, a P/E ratio of 9.75 and a beta of 2.13. InMode Ltd. has a 12-month low of $14.87 and a 12-month high of $26.80. The firm has a fifty day simple moving average of $17.39 and a 200 day simple moving average of $17.21.

Analysts Set New Price Targets

INMD has been the subject of a number of analyst reports. BTIG Research started coverage on InMode in a research report on Thursday, October 17th. They issued a "buy" rating and a $25.00 price target for the company. Barclays raised their target price on shares of InMode from $26.00 to $29.00 and gave the stock an "overweight" rating in a research note on Wednesday. Finally, Needham & Company LLC restated a "hold" rating on shares of InMode in a research report on Tuesday. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $23.00.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.